Results 221 to 230 of about 132,229 (258)

Neoadjuvant chemotherapy for ovarian cancer.

Oncology (Williston Park, N.Y.), 2005
Primary debulking surgery by a gynecologic oncologist remains the standard of care in advanced ovarian cancer. Optimal debulking surgery should be defined as no residual tumor load. In retrospective analyses, neoadjuvant chemotherapy followed by interval debulking surgery does not seem to worsen prognosis compared to primary debulking surgery followed ...
Vergote, Ignace, van Gorp, Toon, Amant, Frederic, Neven, Patrick, Berteloot, Patrick   +4 more
openaire   +2 more sources

Breakthrough for neoadjuvant chemotherapy

Breast Cancer, 2007
Primary breast cancer is considered today as a systemic disease with a locoregional component. Systemic treatment is therefore, considered as a fundamental component of the medical management of patients suffering from this endemic malignancy. Postoperative application of chemo-, endocrine or immunological therapies are always lacking the control of ...
openaire   +1 more source

Neoadjuvant Chemotherapy

Breast Disease, 2004
Marjorie C, Green, Francisco J, Esteva, Gabriel N, Hortobagyi   +2 more
openaire   +2 more sources

Neoadjuvant Chemotherapy

2021
Brandon Bernard, Thomas W. Flaig
openaire   +1 more source

Neoadjuvant Chemotherapy

Nihon rinsho. Japanese journal of clinical medicine, 2013
Filip T. Troicki, Filip T. Troicki, Filip T. Troicki, Carlos A. Perez, Wade L. Thorstad, Brandon J. Fisher, Larry C. Daugherty, Filip T. Troicki, Jaganmohan Poli, Larry C. Daugherty, Brandon J. Fisher, Johannes Classen, Brandon J. Fisher, Larry C. Daugherty, Larry C. Daugherty, Brandon J. Fisher, John P. Lamond, George E. Laramore, Jay J. Liao, Jason K. Rockhill, Jay J. Liao, George E. Laramore, Jason K. Rockhill, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, George E. Laramore, Jay J. Liao, Jason K. Rockhill, Brandon J. Fisher, Larry C. Daugherty, Yan Yu, Laura Doyle, Theodore E. Yaeger, Susan M. Varnum, Marianne B. Sowa, William F. Morgan, James H. Brashears, Darek Michalski, M. Saiful Huq, Brian F. Hasson, Theodore E. Yaeger, Luther W. Brady, Cherie Yaeger, John P. Christodouleas, Edward J. Gracely   +45 more
openaire   +3 more sources

Neoadjuvant and Adjuvant Chemotherapy

2020
Even though the cornerstone of treatment for gallbladder cancer is curative surgical resection, more than two-thirds of the patients are diagnosed with the metastatic condition. Furthermore, prognosis after curative surgery is still poor with a 5-year survival rate less than 5%. Chemotherapy is the main therapeutic option for these situations.
openaire   +1 more source

Survivorship after neoadjuvant chemotherapy

The Lancet Oncology, 2022
Jin, Zhang, Chaoyang, Liang, Wenquan, Niu   +2 more
openaire   +2 more sources

Current and future cancer staging after neoadjuvant treatment for solid tumors

Ca-A Cancer Journal for Clinicians, 2021
James Brierley, Daniel C Sullivan, Thomas P Baker   +2 more
exaly  

Neoadjuvant chemotherapy in oesophageal adenocarcinoma

The Lancet Oncology, 2017
van Laarhoven, Hanneke W. M., van Berge Henegouwen, Mark I., Hulshof, Maarten C. C. M.   +2 more
openaire   +4 more sources

[Radiotherapy with neoadjuvant chemotherapy].

Annales de medecine interne, 1990
Neoadjuvant chemotherapy can be used before radiotherapy to combat microscopic metastatic loci and to facilitate irradiation. Improvement in the survival time by impeding the dissemination of metastases seems to be real for breast cancer, but has not been observed to date in randomized studies of ENT cancers.
F, Baillet, M, Housset, B, Dessard-Diana, C, Jacquillat, P, Michel-Langlet, C, Alapetite   +5 more
openaire   +1 more source